The efficiency of a urotensin II antagonist in an experimental lung fibrosis model.
Pulmonary fibrosis is a chronic disease. Urotensin II (U-II) is a new peptide with angiogenic and profibrotic features. Therefore, we aim to evaluate the antagonism of U-II with palosuran in an animal model and plan to measure U-II, endothelin-1 (ET-1), and transforming growth factor-β1 (TGF-β1) and their association with lung fibrosis. Thirty Wistar male rats were used in the study and were divided into three groups: group 1, control; group 2, bleomycin-induced lung fibrosis group; and group 3, bleomycin-induced lung fibrosis with treatment palosuran group. U-II level (nanograms per milliliter) was 2.957 ± 0.159 in group1, 3.188 ± 0.122 in group 2, and 2.970 ± 0.165 in group 3 (p = 0.002). The ET-1 level (picograms per milliliter) was 4.486 ± 0.376 in group 1, 9.086 ± 1.850 in group 2, and 4.486 ± 0.376 in group 3 (p < 0.001). The TGF-β1 (nanograms per milliliter) level was 73.143 ± 9.96 in group 1, 84.81 ± 4.73 in group 2, and 77.86 ± 5.77 in group 3 (p = 0.006). Finally, the fibrosis score was 0.7 ± 0.48 in group 1, 4.4 ± 1.34 in group 2, and 3.2 ± 0.63 in group 3 (p < 0.001). There is a statistically significant positive relationship between fibrosis scores and the UT-II, ET-1, and TGF-β1 levels of the experimental lung fibrosis model. We believe U-II is an important mediator in lung fibrosis models, and its antagonism with palosuran could be a new treatment choice for interstitial lung fibrosis, but further studies need to be conducted to verify the findings of the current study.
Department of Rheumatology, Sahinbey Medical Center, School of Medicine, Gaziantep University, Gaziantep 27310, Turkey.
Ahmet Mesut
AM
Onat
Ibrahim Halil
IH
Turkbeyler
Yavuz
Y
Pehlivan
Tuncer
T
Demir
Davut Sinan
DS
Kaplan
Seyithan
S
Taysi
Ali Osman
AO
Ceribasi
Ediz
E
Tutar
Bunyamin
B
Kisacik
D000818:Animals; D001761:Bleomycin; D019332:Endothelin-1 / Q000032:analysis; D008168:Lung / Q000473:pathology; D008297:Male; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D053773:Transforming Growth Factor beta1 / Q000032:analysis; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014579:Urotensins / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D019332:Endothelin-1; D011804:Quinolines; D053773:Transforming Growth Factor beta1; D014579:Urotensins; D001761:Bleomycin; D014508:Urea; C029677:urotensin II; C493249:1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea